These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 14754430)

  • 1. Resistance to HIV-1 entry inhibitors.
    Olson WC; Maddon PJ
    Curr Drug Targets Infect Disord; 2003 Dec; 3(4):283-94. PubMed ID: 14754430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV fusion and its inhibition.
    LaBranche CC; Galasso G; Moore JP; Bolognesi DP; Hirsch MS; Hammer SM
    Antiviral Res; 2001 May; 50(2):95-115. PubMed ID: 11369431
    [No Abstract]   [Full Text] [Related]  

  • 3. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
    Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity.
    Reeves JD; Miamidian JL; Biscone MJ; Lee FH; Ahmad N; Pierson TC; Doms RW
    J Virol; 2004 May; 78(10):5476-85. PubMed ID: 15113926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV entry and fusion inhibitors.
    Chantry D
    Expert Opin Emerg Drugs; 2004 May; 9(1):1-7. PubMed ID: 15155132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.
    Ray N; Harrison JE; Blackburn LA; Martin JN; Deeks SG; Doms RW
    J Virol; 2007 Apr; 81(7):3240-50. PubMed ID: 17251281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells.
    Ketas TJ; Frank I; Klasse PJ; Sullivan BM; Gardner JP; Spenlehauer C; Nesin M; Olson WC; Moore JP; Pope M
    J Virol; 2003 Feb; 77(4):2762-7. PubMed ID: 12552019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
    Platt EJ; Durnin JP; Kabat D
    J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to enfuvirtide, the first HIV fusion inhibitor.
    Greenberg ML; Cammack N
    J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The current progress in the development of HIV-1 fusion inhibitors].
    Shi WG; Jia QY; Liu KL
    Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion.
    Nagashima KA; Thompson DA; Rosenfield SI; Maddon PJ; Dragic T; Olson WC
    J Infect Dis; 2001 Apr; 183(7):1121-5. PubMed ID: 11237840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of primary resistance to HIV entry inhibitors among brazilian patients failing reverse transcriptase/protease inhibitors treatment reveal high prevalence of maraviroc resistance-related mutations.
    Alencar CS; Nishiya AS; Ferreira S; Giret MT; Diaz RS; Sabino EC
    AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1267-71. PubMed ID: 20977300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favorable interactions between enfuvirtide and 1-beta-D-2,6-diaminopurine dioxolane in vitro.
    Tremblay CL; Poulin DL; Hicks JL; Selliah S; Chamberland A; Giguel F; Kollmann CS; Chou TC; Dong H; Hirsch MS
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3644-6. PubMed ID: 14576137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid.
    van Lelyveld SF; Nijhuis M; Baatz F; Wilting I; van den Bergh WM; Kurowski M; de Jong D; Hoepelman AI; Wensing AM
    Clin Infect Dis; 2010 Feb; 50(3):387-90. PubMed ID: 20047481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential for HIV fusion inhibition.
    Cammack N
    Curr Opin Infect Dis; 2001 Feb; 14(1):13-6. PubMed ID: 11979109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV entry inhibitors.
    Esté JA; Telenti A
    Lancet; 2007 Jul; 370(9581):81-8. PubMed ID: 17617275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV entry inhibitors: a new generation of antiretroviral drugs.
    Krambovitis E; Porichis F; Spandidos DA
    Acta Pharmacol Sin; 2005 Oct; 26(10):1165-73. PubMed ID: 16174430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline susceptibility of primary HIV-2 to entry inhibitors.
    Borrego P; Calado R; Marcelino JM; Bártolo I; Rocha C; Cavaco-Silva P; Doroana M; Antunes F; Maltez F; Caixas U; Barroso H; Taveira N
    Antivir Ther; 2012; 17(3):565-70. PubMed ID: 22293827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.
    Reeves JD; Lee FH; Miamidian JL; Jabara CB; Juntilla MM; Doms RW
    J Virol; 2005 Apr; 79(8):4991-9. PubMed ID: 15795284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.
    Fung HB; Guo Y
    Clin Ther; 2004 Mar; 26(3):352-78. PubMed ID: 15110129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.